Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03AKH
|
|||
| Former ID |
DNCL001755
|
|||
| Drug Name |
CER-001
|
|||
| Indication | Acute coronary syndrome [ICD-11: BA41; ICD-9: 411.1] | Phase 2 | [1] | |
| Cardiovascular disease [ICD-11: BA00-BE2Z; ICD-10: I00-I99, E78; ICD-9: 390-459] | Phase 2 | [2] | ||
| Company |
Cerenis Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01412034) Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of Cerenis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.